Latest Earnings Results: Q3 '26
Estimated EPS
-$0.65
Reported EPS
-$0.09
Surprise
+86.15%
Estimated Rev
$86.3M
Reported Rev
$90.41M
Surprise
+4.76%
• Reported GAAP EPS of -$0.09 down -164.29% YoY • Reported revenue of $90.41M up 7.54% YoY • Fulgent Genetics expects its collection rate and corresponding gross margin to improve as remaining billing-system customizations are completed, while research and development expenses are expected to increase as clinical trials progress.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.68 | -- | -- | N/A |
Q3 '26 | -$0.65 | -$0.09 | 86.15% | BEAT |
Q2 '26 | -$0.46 | -$0.58 | -26.09% | MISSED |
Q1 '26 | -$0.35 | -$0.36 | -3.40% | MISSED |
Q4 '25 | $0.03 | $0.16 | 436.32% | BEAT |